Premium
Prohibition against competing cancer clinical trials
Author(s) -
Markman Maurie
Publication year - 2007
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.23202
Subject(s) - medicine , clinical trial , cancer , selection (genetic algorithm) , quality (philosophy) , action (physics) , intensive care medicine , risk analysis (engineering) , pathology , epistemology , artificial intelligence , computer science , philosophy , physics , quantum mechanics
The arbitrary decision to prevent the existence of competing trials within an individual cancer program based on the notion that selection bias will be reduced and the quality of the research will be enhanced is a poorly considered action. Furthermore, it has the very legitimate potential to be counterproductive by interfering with the societal goal of increasing the number of cancer patients who enter important clinical studies.